Lampros G Chrysavgis (Lampros Chrysavgis)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Ankylosing Spondylitis

Glycemic Control

Hepatitis B Virus

Top Venues

International journal of molecular sciences

Pathogens (Basel, Switzerland)

Journal of gastroenterology and hepatology

European journal of clinical investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Lampros G Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongitas
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International journal of molecular sciences 25 (7) (2024)
Lampros G Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongitas
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International journal of molecular sciences 25 (7) (2024)
Lampros G Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongitas
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International journal of molecular sciences 25 (7) (2024)
Lampros G Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongitas
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International journal of molecular sciences 25 (7) (2024)
Nikolaos D Karakousis, Lampros G Chrysavgis, Alkistis Papatheodoridi, Aigli-Ioanna Legaki, Panagiotis Lembessis, Evangelos Cholongitas, Antonios Chatzigeorgiou, Georgios Papatheodoridis
Significance of Circulating Cell-Free DNA Biomarkers in HBeAg-Negative Chronic Hepatitis B Virus Infection and Their Changes after Treatment Initiation. Pathogens (Basel, Switzerland) 12 (3) (2023)
Nikolaos D Karakousis, Lampros G Chrysavgis, Alkistis Papatheodoridi, Aigli-Ioanna Legaki, Panagiotis Lembessis, Evangelos Cholongitas, Antonios Chatzigeorgiou, Georgios Papatheodoridis
Significance of Circulating Cell-Free DNA Biomarkers in HBeAg-Negative Chronic Hepatitis B Virus Infection and Their Changes after Treatment Initiation. Pathogens (Basel, Switzerland) 12 (3) (2023)
Nikolaos D Karakousis, Lampros G Chrysavgis, Alkistis Papatheodoridi, Aigli-Ioanna Legaki, Panagiotis Lembessis, Evangelos Cholongitas, Antonios Chatzigeorgiou, Georgios Papatheodoridis
Significance of Circulating Cell-Free DNA Biomarkers in HBeAg-Negative Chronic Hepatitis B Virus Infection and Their Changes after Treatment Initiation. Pathogens (Basel, Switzerland) 12 (3) (2023)
Lampros G Chrysavgis, Magdalini Adamantou, Anna Angelousi, Evangelos Cholongitas
The association of testosterone with sarcopenia and frailty in chronic liver disease. European journal of clinical investigation (2023)
Lampros G Chrysavgis, Evangelos Cholongitas
Acute Severe Hepatitis of Unknown Origin in Children Across the World: A 2022 Source of Concern. Journal of clinical and translational hepatology 10 (3) (2022)
Lampros G Chrysavgis, Alkistis-Maria Papatheodoridi, Antonios Chatzigeorgiou, Evangelos Cholongitas
The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. Journal of gastroenterology and hepatology 36 (4) (2020)